J&J bumps up full-year profit view on strength of cancer drugs

Johnson & Johnson on Tuesday boosted its full-year adjusted profit forecast, as multi-billion dollar sales of its cancer drugs Darzalex and Imbruvica helped it beat estimates for third-quarter profit.